PFKFB3 and benign neoplasm: The significantly higher expression of PFKFB3 in the stroma of benign neoplasms compared to malignant CRC tissues suggests a dynamic regulation of this metabolic enzyme during cancer progression, potentially reflecting an early host anti-tumor response that becomes suppressed or reprogrammed in advanced disease.